Ketamina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ketamina" in Italian language version.

refsWebsite

Global rank Italian rank

29nih.gov

4^th place

9^th place

26doi.org

2^nd place

7^th place

13oadoi.org

799^th place

22^nd place

3web.archive.org

1^st place

2archive.org

6^th place

8^th place

1sciencedaily.com

993^rd place

1,228^th place

1psychiatryonline.org

4,032^nd place

3,374^th place

1focus.it

7,805^th place

271^st place

1torrinomedica.it

low place

2,002^nd place

1psychedelicreview.com

low place

1worldcat.org

5^th place

26^th place

1unibo.it

4,963^rd place

325^th place

1npr.org

92^nd place

290^th place

1tumblr.com

784^th place

838^th place

archive.org

Peck T.E., Hill S.A., Williams M., Pharmacology for anaesthesia and intensive care (3rd edition), Cambridge University Press, Cambridge, 2008, p. 111, ISBN 978-0-521-70463-2.
JW. Murrough, DV. Iosifescu; LC. Chang; RK. Al Jurdi; CE. Green; AM. Perez; S. Iqbal; S. Pillemer; A. Foulkes; A. Shah; DS. Charney, Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial., in Am J Psychiatry, vol. 170, n. 10, Oct 2013, pp. 1134-42, DOI:10.1176/appi.ajp.2013.13030392, PMID 23982301.

doi.org

dx.doi.org

Celia J. A. Morgan, Lisa Monaghan e H. Valerie Curran, Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug, in Addiction, vol. 99, n. 11, 2004-11, pp. 1450-1461, DOI:10.1111/j.1360-0443.2004.00879.x. URL consultato il 26 novembre 2018.
Sarah E. Grady, Travis A. Marsh e Allison Tenhouse, Ketamine for the treatment of major depressive disorder and bipolar depression: A review of the literature, in The Mental Health Clinician, vol. 7, n. 1, 23 marzo 2018, pp. 16-23, DOI:10.9740/mhc.2017.01.016. URL consultato il 15 aprile 2019.
Adriana Feder, Michael K. Parides e James W. Murrough, Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder, in JAMA Psychiatry, vol. 71, n. 6, 1º giugno 2014, p. 681, DOI:10.1001/jamapsychiatry.2014.62. URL consultato il 21 novembre 2018.
Sara Costi, Nicholas T. Van Dam e James W. Murrough, Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders, in Current behavioral neuroscience reports, vol. 2, n. 4, 2015-12, pp. 216-225, DOI:10.1007/s40473-015-0052-3. URL consultato il 15 aprile 2019.
Amy McAndrew, Will Lawn e Tobias Stevens, A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial, in Trials, vol. 18, 4 aprile 2017, DOI:10.1186/s13063-017-1895-6. URL consultato il 15 aprile 2019.
Meryem Grabski, Amy McAndrew e Will Lawn, Adjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder, in American Journal of Psychiatry, 11 gennaio 2022, pp. appi.ajp.2021.21030277, DOI:10.1176/appi.ajp.2021.21030277. URL consultato il 13 gennaio 2022.
FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic, in Case Medical Research, 5 marzo 2019, DOI:10.31525/fda2-ucm632761.htm. URL consultato il 22 maggio 2020.
BH. Pypendop, JE. Ilkiw, Pharmacokinetics of ketamine and its metabolite, norketamine, after intravenous administration of a bolus of ketamine to isoflurane-anesthetized dogs., in Am J Vet Res, vol. 66, n. 12, dicembre 2004, pp. 2034-8, DOI:10.2460/ajvr.2005.66.2034, PMID 16379643.
EE. Prommer, Ketamine for pain: an update of uses in palliative care., in J Palliat Med, vol. 15, n. 4, aprile 2012, pp. 474-83, DOI:10.1089/jpm.2011.0244, PMID 22500483.
(EN) Panos Zanos, Ruin Moaddel, Patrick J. Morris, Polymnia Georgiou, Jonathan Fischell, Greg I. Elmer, Manickavasagom Alkondon, Peixiong Yuan, Heather J. Pribut, Nagendra S. Singh, Katina S. S. Dossou, Yuhong Fang, Xi-Ping Huang, Cheryl L. Mayo, Irving W. Wainer, Edson X. Albuquerque, Scott M. Thompson, Craig J. Thomas, Carlos A. Zarate Jr e Todd D. Gould, NMDAR inhibition-independent antidepressant actions of ketamine metabolites, in Nature, n. 533, 26 maggio 2016, pp. 481-486, DOI:10.1038/nature17998, ISSN 0028-0836 (WC · ACNP).
K. Hirota, KS. Sikand; DG. Lambert, Interaction of ketamine with mu2 opioid receptors in SH-SY5Y human neuroblastoma cells., in J Anesth, vol. 13, n. 2, 1999, pp. 107-9, DOI:10.1007/s005400050035, PMID 14530949.
S. Koizuka, H. Obata; M. Sasaki; S. Saito; F. Goto, Systemic ketamine inhibits hypersensitivity after surgery via descending inhibitory pathways in rats., in Can J Anaesth, vol. 52, n. 5, maggio 2005, pp. 498-505, DOI:10.1007/BF03016530, PMID 15872129.
F. Heshmati, MB. Zeinali; H. Noroozinia; R. Abbacivash; A. Mahoori, Use of ketamine in severe status asthmaticus in intensive care unit., in Iran J Allergy Asthma Immunol, vol. 2, n. 4, dicembre 2003, pp. 175-80, DOI:10.02.04/ijaai.175180, PMID 17301376.
SE. Lankenau, B. Sanders; JJ. Bloom; D. Hathazi; E. Alarcon; S. Tortu; MC. Clatts, First injection of ketamine among young injection drug users (IDUs) in three U.S. cities., in Drug Alcohol Depend, vol. 87, n. 2-3, marzo 2007, pp. 183-93, DOI:10.1016/j.drugalcdep.2006.08.015, PMID 16979848.
(EN) P. Molero, J. A. Ramos-Quiroga e R. Martin-Santos, Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review, in CNS Drugs, vol. 32, n. 5, 1º maggio 2018, pp. 411-420, DOI:10.1007/s40263-018-0519-3. URL consultato il 15 aprile 2019.
T. S. Sathyanarayana Rao e Chittaranjan Andrade, A possible role for ketamine in suicide prevention in emergency and mainstream psychiatry, in Indian Journal of Psychiatry, vol. 59, n. 3, 2017, pp. 259-261, DOI:10.4103/psychiatry.IndianJPsychiatry_345_17. URL consultato il 15 aprile 2019.
AE. Autry, M. Adachi; E. Nosyreva; ES. Na; MF. Los; PF. Cheng; ET. Kavalali; LM. Monteggia, NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses., in Nature, vol. 475, n. 7354, luglio 2011, pp. 91-5, DOI:10.1038/nature10130, PMID 21677641.
JW. Murrough, DV. Iosifescu; LC. Chang; RK. Al Jurdi; CE. Green; AM. Perez; S. Iqbal; S. Pillemer; A. Foulkes; A. Shah; DS. Charney, Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial., in Am J Psychiatry, vol. 170, n. 10, Oct 2013, pp. 1134-42, DOI:10.1176/appi.ajp.2013.13030392, PMID 23982301.
JW. Murrough, AM. Perez; S. Pillemer; J. Stern; MK. Parides; M. aan het Rot; KA. Collins; SJ. Mathew; DS. Charney; DV. Iosifescu, Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression., in Biol Psychiatry, vol. 74, n. 4, Aug 2013, pp. 250-6, DOI:10.1016/j.biopsych.2012.06.022, PMID 22840761.
F. Segmiller, T. Rüther; A. Linhardt; F. Padberg; M. Berger; O. Pogarell; HJ. Möller; C. Kohler; C. Schüle, Repeated S-ketamine infusions in therapy resistant depression: a case series., in J Clin Pharmacol, vol. 53, n. 9, Sep 2013, pp. 996-8, DOI:10.1002/jcph.122, PMID 23893490.
KG. Rasmussen, TW. Lineberry; CW. Galardy; S. Kung; MI. Lapid; BA. Palmer; MJ. Ritter; KM. Schak; CL. Sola; AJ. Hanson; MA. Frye, Serial infusions of low-dose ketamine for major depression., in J Psychopharmacol, vol. 27, n. 5, maggio 2013, pp. 444-50, DOI:10.1177/0269881113478283, PMID 23428794.
CG. Abdallah, M. Fasula; B. Kelmendi; G. Sanacora; R. Ostroff, Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting., in J ECT, vol. 28, n. 3, Sep 2012, pp. 157-61, DOI:10.1097/YCT.0b013e31824f8296, PMID 22847373.
K. Järventausta, W. Chrapek; O. Kampman; K. Tuohimaa; M. Björkqvist; H. Häkkinen; A. Yli-Hankala; E. Leinonen, Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study., in J ECT, vol. 29, n. 3, Sep 2013, pp. 158-61, DOI:10.1097/YCT.0b013e318283b7e9, PMID 23475029.
Lindsay Cohen, Valerie Athaide e Maeve E. Wickham, The effect of ketamine on intracranial and cerebral perfusion pressure and health outcomes: a systematic review, in Annals of Emergency Medicine, vol. 65, n. 1, 2015-01, pp. 43–51.e2, DOI:10.1016/j.annemergmed.2014.06.018. URL consultato il 24 luglio 2020.
Christian Zanza, Fabio Piccolella e Fabrizio Racca, Ketamine in Acute Brain Injury: Current Opinion Following Cerebral Circulation and Electrical Activity, in Healthcare (Basel, Switzerland), vol. 10, n. 3, 17 marzo 2022, pp. 566, DOI:10.3390/healthcare10030566. URL consultato il 4 aprile 2022.

doi.org

(EN) P. Molero, J. A. Ramos-Quiroga e R. Martin-Santos, Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review, in CNS Drugs, vol. 32, n. 5, 1º maggio 2018, pp. 411-420, DOI:10.1007/s40263-018-0519-3. URL consultato il 15 aprile 2019.

focus.it

La tripla vita della ketamina, su Focus.it. URL consultato il 15 aprile 2019.

nih.gov

ncbi.nlm.nih.gov

Sarah E. Grady, Travis A. Marsh e Allison Tenhouse, Ketamine for the treatment of major depressive disorder and bipolar depression: A review of the literature, in The Mental Health Clinician, vol. 7, n. 1, 23 marzo 2018, pp. 16-23, DOI:10.9740/mhc.2017.01.016. URL consultato il 15 aprile 2019.
Sara Costi, Nicholas T. Van Dam e James W. Murrough, Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders, in Current behavioral neuroscience reports, vol. 2, n. 4, 2015-12, pp. 216-225, DOI:10.1007/s40473-015-0052-3. URL consultato il 15 aprile 2019.
Amy McAndrew, Will Lawn e Tobias Stevens, A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial, in Trials, vol. 18, 4 aprile 2017, DOI:10.1186/s13063-017-1895-6. URL consultato il 15 aprile 2019.
A.D. Krüger, Current aspects of using ketamine in childhood, in Anaesthesiologie Und Reanimation, vol. 23, n. 3, 1998, pp. 64-71, PMID 9707751.
J. Wieber, R. Gugler; JH. Hengstmann; HJ. Dengler, Pharmacokinetics of ketamine in man., in Anaesthesist, vol. 24, n. 6, giugno 1975, pp. 260-3, PMID 1155748.
BH. Pypendop, JE. Ilkiw, Pharmacokinetics of ketamine and its metabolite, norketamine, after intravenous administration of a bolus of ketamine to isoflurane-anesthetized dogs., in Am J Vet Res, vol. 66, n. 12, dicembre 2004, pp. 2034-8, DOI:10.2460/ajvr.2005.66.2034, PMID 16379643.
EE. Prommer, Ketamine for pain: an update of uses in palliative care., in J Palliat Med, vol. 15, n. 4, aprile 2012, pp. 474-83, DOI:10.1089/jpm.2011.0244, PMID 22500483.
K. Hirota, KS. Sikand; DG. Lambert, Interaction of ketamine with mu2 opioid receptors in SH-SY5Y human neuroblastoma cells., in J Anesth, vol. 13, n. 2, 1999, pp. 107-9, DOI:10.1007/s005400050035, PMID 14530949.
ME. Durieux, Inhibition by ketamine of muscarinic acetylcholine receptor function., in Anesth Analg, vol. 81, n. 1, luglio 1995, pp. 57-62, PMID 7598283.
S. Koizuka, H. Obata; M. Sasaki; S. Saito; F. Goto, Systemic ketamine inhibits hypersensitivity after surgery via descending inhibitory pathways in rats., in Can J Anaesth, vol. 52, n. 5, maggio 2005, pp. 498-505, DOI:10.1007/BF03016530, PMID 15872129.
SA. Bergman, Ketamine: review of its pharmacology and its use in pediatric anesthesia., in Anesth Prog, vol. 46, n. 1, 1999, pp. 10-20, PMID 10551055.
JW. Olney, J. Labruyere; MT. Price, Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs., in Science, vol. 244, n. 4910, giugno 1989, pp. 1360-2, PMID 2660263.
F. Heshmati, MB. Zeinali; H. Noroozinia; R. Abbacivash; A. Mahoori, Use of ketamine in severe status asthmaticus in intensive care unit., in Iran J Allergy Asthma Immunol, vol. 2, n. 4, dicembre 2003, pp. 175-80, DOI:10.02.04/ijaai.175180, PMID 17301376.
SE. Lankenau, B. Sanders; JJ. Bloom; D. Hathazi; E. Alarcon; S. Tortu; MC. Clatts, First injection of ketamine among young injection drug users (IDUs) in three U.S. cities., in Drug Alcohol Depend, vol. 87, n. 2-3, marzo 2007, pp. 183-93, DOI:10.1016/j.drugalcdep.2006.08.015, PMID 16979848.
Ketamine as antidepressant? Current stat... [Curr Neuropharmacol. 2014] - PubMed - NCBI, su ncbi.nlm.nih.gov. URL consultato il 6 aprile 2014.
T. S. Sathyanarayana Rao e Chittaranjan Andrade, A possible role for ketamine in suicide prevention in emergency and mainstream psychiatry, in Indian Journal of Psychiatry, vol. 59, n. 3, 2017, pp. 259-261, DOI:10.4103/psychiatry.IndianJPsychiatry_345_17. URL consultato il 15 aprile 2019.
AE. Autry, M. Adachi; E. Nosyreva; ES. Na; MF. Los; PF. Cheng; ET. Kavalali; LM. Monteggia, NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses., in Nature, vol. 475, n. 7354, luglio 2011, pp. 91-5, DOI:10.1038/nature10130, PMID 21677641.
Pubmed: ketamine depression - PubMed - NCBI, su ncbi.nlm.nih.gov, 6 aprile 2014. URL consultato il 6 aprile 2014.
JW. Murrough, DV. Iosifescu; LC. Chang; RK. Al Jurdi; CE. Green; AM. Perez; S. Iqbal; S. Pillemer; A. Foulkes; A. Shah; DS. Charney, Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial., in Am J Psychiatry, vol. 170, n. 10, Oct 2013, pp. 1134-42, DOI:10.1176/appi.ajp.2013.13030392, PMID 23982301.
JW. Murrough, AM. Perez; S. Pillemer; J. Stern; MK. Parides; M. aan het Rot; KA. Collins; SJ. Mathew; DS. Charney; DV. Iosifescu, Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression., in Biol Psychiatry, vol. 74, n. 4, Aug 2013, pp. 250-6, DOI:10.1016/j.biopsych.2012.06.022, PMID 22840761.
F. Segmiller, T. Rüther; A. Linhardt; F. Padberg; M. Berger; O. Pogarell; HJ. Möller; C. Kohler; C. Schüle, Repeated S-ketamine infusions in therapy resistant depression: a case series., in J Clin Pharmacol, vol. 53, n. 9, Sep 2013, pp. 996-8, DOI:10.1002/jcph.122, PMID 23893490.
P. Sos, M. Klirova; T. Novak; B. Kohutova; J. Horacek; T. Palenicek, Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression., in Neuro Endocrinol Lett, vol. 34, n. 4, 2013, pp. 287-93, PMID 23803871.
KG. Rasmussen, TW. Lineberry; CW. Galardy; S. Kung; MI. Lapid; BA. Palmer; MJ. Ritter; KM. Schak; CL. Sola; AJ. Hanson; MA. Frye, Serial infusions of low-dose ketamine for major depression., in J Psychopharmacol, vol. 27, n. 5, maggio 2013, pp. 444-50, DOI:10.1177/0269881113478283, PMID 23428794.
CG. Abdallah, M. Fasula; B. Kelmendi; G. Sanacora; R. Ostroff, Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting., in J ECT, vol. 28, n. 3, Sep 2012, pp. 157-61, DOI:10.1097/YCT.0b013e31824f8296, PMID 22847373.
K. Järventausta, W. Chrapek; O. Kampman; K. Tuohimaa; M. Björkqvist; H. Häkkinen; A. Yli-Hankala; E. Leinonen, Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study., in J ECT, vol. 29, n. 3, Sep 2013, pp. 158-61, DOI:10.1097/YCT.0b013e318283b7e9, PMID 23475029.
Ketamine as the prototype glutamate... [Ther Adv Psychopharmacol. 2014] - PubMed - NCBI, su ncbi.nlm.nih.gov. URL consultato il 6 aprile 2014.
Lindsay Cohen, Valerie Athaide e Maeve E. Wickham, The effect of ketamine on intracranial and cerebral perfusion pressure and health outcomes: a systematic review, in Annals of Emergency Medicine, vol. 65, n. 1, 2015-01, pp. 43–51.e2, DOI:10.1016/j.annemergmed.2014.06.018. URL consultato il 24 luglio 2020.

directorsblog.nih.gov

(EN) Francis Collins, Fighting Depression: Ketamine Metabolite May Offer Benefits Without the Risks, su Director's Blog, National Institutes of Health, 10 maggio 2016. URL consultato il 6 giugno 2016.

pubmed.ncbi.nlm.nih.gov

Christian Zanza, Fabio Piccolella e Fabrizio Racca, Ketamine in Acute Brain Injury: Current Opinion Following Cerebral Circulation and Electrical Activity, in Healthcare (Basel, Switzerland), vol. 10, n. 3, 17 marzo 2022, pp. 566, DOI:10.3390/healthcare10030566. URL consultato il 4 aprile 2022.

npr.org

(EN) FDA Approves Esketamine Nasal Spray For Hard-To-Treat Depression, su NPR.org. URL consultato il 6 marzo 2019.

oadoi.org

BH. Pypendop, JE. Ilkiw, Pharmacokinetics of ketamine and its metabolite, norketamine, after intravenous administration of a bolus of ketamine to isoflurane-anesthetized dogs., in Am J Vet Res, vol. 66, n. 12, dicembre 2004, pp. 2034-8, DOI:10.2460/ajvr.2005.66.2034, PMID 16379643.
EE. Prommer, Ketamine for pain: an update of uses in palliative care., in J Palliat Med, vol. 15, n. 4, aprile 2012, pp. 474-83, DOI:10.1089/jpm.2011.0244, PMID 22500483.
(EN) Panos Zanos, Ruin Moaddel, Patrick J. Morris, Polymnia Georgiou, Jonathan Fischell, Greg I. Elmer, Manickavasagom Alkondon, Peixiong Yuan, Heather J. Pribut, Nagendra S. Singh, Katina S. S. Dossou, Yuhong Fang, Xi-Ping Huang, Cheryl L. Mayo, Irving W. Wainer, Edson X. Albuquerque, Scott M. Thompson, Craig J. Thomas, Carlos A. Zarate Jr e Todd D. Gould, NMDAR inhibition-independent antidepressant actions of ketamine metabolites, in Nature, n. 533, 26 maggio 2016, pp. 481-486, DOI:10.1038/nature17998, ISSN 0028-0836 (WC · ACNP).
K. Hirota, KS. Sikand; DG. Lambert, Interaction of ketamine with mu2 opioid receptors in SH-SY5Y human neuroblastoma cells., in J Anesth, vol. 13, n. 2, 1999, pp. 107-9, DOI:10.1007/s005400050035, PMID 14530949.
S. Koizuka, H. Obata; M. Sasaki; S. Saito; F. Goto, Systemic ketamine inhibits hypersensitivity after surgery via descending inhibitory pathways in rats., in Can J Anaesth, vol. 52, n. 5, maggio 2005, pp. 498-505, DOI:10.1007/BF03016530, PMID 15872129.
F. Heshmati, MB. Zeinali; H. Noroozinia; R. Abbacivash; A. Mahoori, Use of ketamine in severe status asthmaticus in intensive care unit., in Iran J Allergy Asthma Immunol, vol. 2, n. 4, dicembre 2003, pp. 175-80, DOI:10.02.04/ijaai.175180, PMID 17301376.
SE. Lankenau, B. Sanders; JJ. Bloom; D. Hathazi; E. Alarcon; S. Tortu; MC. Clatts, First injection of ketamine among young injection drug users (IDUs) in three U.S. cities., in Drug Alcohol Depend, vol. 87, n. 2-3, marzo 2007, pp. 183-93, DOI:10.1016/j.drugalcdep.2006.08.015, PMID 16979848.
AE. Autry, M. Adachi; E. Nosyreva; ES. Na; MF. Los; PF. Cheng; ET. Kavalali; LM. Monteggia, NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses., in Nature, vol. 475, n. 7354, luglio 2011, pp. 91-5, DOI:10.1038/nature10130, PMID 21677641.
JW. Murrough, AM. Perez; S. Pillemer; J. Stern; MK. Parides; M. aan het Rot; KA. Collins; SJ. Mathew; DS. Charney; DV. Iosifescu, Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression., in Biol Psychiatry, vol. 74, n. 4, Aug 2013, pp. 250-6, DOI:10.1016/j.biopsych.2012.06.022, PMID 22840761.
F. Segmiller, T. Rüther; A. Linhardt; F. Padberg; M. Berger; O. Pogarell; HJ. Möller; C. Kohler; C. Schüle, Repeated S-ketamine infusions in therapy resistant depression: a case series., in J Clin Pharmacol, vol. 53, n. 9, Sep 2013, pp. 996-8, DOI:10.1002/jcph.122, PMID 23893490.
KG. Rasmussen, TW. Lineberry; CW. Galardy; S. Kung; MI. Lapid; BA. Palmer; MJ. Ritter; KM. Schak; CL. Sola; AJ. Hanson; MA. Frye, Serial infusions of low-dose ketamine for major depression., in J Psychopharmacol, vol. 27, n. 5, maggio 2013, pp. 444-50, DOI:10.1177/0269881113478283, PMID 23428794.
CG. Abdallah, M. Fasula; B. Kelmendi; G. Sanacora; R. Ostroff, Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting., in J ECT, vol. 28, n. 3, Sep 2012, pp. 157-61, DOI:10.1097/YCT.0b013e31824f8296, PMID 22847373.
K. Järventausta, W. Chrapek; O. Kampman; K. Tuohimaa; M. Björkqvist; H. Häkkinen; A. Yli-Hankala; E. Leinonen, Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study., in J ECT, vol. 29, n. 3, Sep 2013, pp. 158-61, DOI:10.1097/YCT.0b013e318283b7e9, PMID 23475029.

psychedelicreview.com

(EN) Melody Pezeshkian, The Nuances of Ketamine’s Neurochemistry, su Psychedelic Science Review, 15 febbraio 2021. URL consultato il 16 febbraio 2021.

psychiatryonline.org

ajp.psychiatryonline.org

Meryem Grabski, Amy McAndrew e Will Lawn, Adjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder, in American Journal of Psychiatry, 11 gennaio 2022, pp. appi.ajp.2021.21030277, DOI:10.1176/appi.ajp.2021.21030277. URL consultato il 13 gennaio 2022.

sciencedaily.com

Ketamine improved bipolar depression within minutes, study suggests, in Science Daily, 30 maggio 2012. URL consultato il 24 novembre 2016.

torrinomedica.it

Sandro Magnanelli, Ketamina Molt: Scheda Tecnica e Prescrivibilità, su Torrinomedica, 11 febbraio 2018. URL consultato il 15 aprile 2019.

tumblr.com

tranxcend.tumblr.com

Woodard, D., “The Ketamine Necromance”, nel A. Parfrey, Apocalypse Culture II (Los Angeles: Feral House, 2000), pp. 288–295.

unibo.it

acnpsearch.unibo.it

(EN) Panos Zanos, Ruin Moaddel, Patrick J. Morris, Polymnia Georgiou, Jonathan Fischell, Greg I. Elmer, Manickavasagom Alkondon, Peixiong Yuan, Heather J. Pribut, Nagendra S. Singh, Katina S. S. Dossou, Yuhong Fang, Xi-Ping Huang, Cheryl L. Mayo, Irving W. Wainer, Edson X. Albuquerque, Scott M. Thompson, Craig J. Thomas, Carlos A. Zarate Jr e Todd D. Gould, NMDAR inhibition-independent antidepressant actions of ketamine metabolites, in Nature, n. 533, 26 maggio 2016, pp. 481-486, DOI:10.1038/nature17998, ISSN 0028-0836 (WC · ACNP).

web.archive.org

WHO world health organization, Essential Medicines. WHO Model List (revised March 2005) (PDF), su whqlibdoc.who.int, marzo 2005. URL consultato il 6 aprile 2013 (archiviato dall'url originale il 12 febbraio 2007).
(EN) Antidepressant Compound Located That May Come With Zero Side Effects, in Science News Journal, 6 maggio 2016. URL consultato il 6 giugno 2016 (archiviato dall'url originale il 2 giugno 2016).
Ketamine: Drug Information Provided by Lexi-Comp: Merck Manual Professional, su web.archive.org, 9 marzo 2011. URL consultato il 24 luglio 2020 (archiviato dall'url originale il 9 marzo 2011).

worldcat.org

(EN) Panos Zanos, Ruin Moaddel, Patrick J. Morris, Polymnia Georgiou, Jonathan Fischell, Greg I. Elmer, Manickavasagom Alkondon, Peixiong Yuan, Heather J. Pribut, Nagendra S. Singh, Katina S. S. Dossou, Yuhong Fang, Xi-Ping Huang, Cheryl L. Mayo, Irving W. Wainer, Edson X. Albuquerque, Scott M. Thompson, Craig J. Thomas, Carlos A. Zarate Jr e Todd D. Gould, NMDAR inhibition-independent antidepressant actions of ketamine metabolites, in Nature, n. 533, 26 maggio 2016, pp. 481-486, DOI:10.1038/nature17998, ISSN 0028-0836 (WC · ACNP).